

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant: Bruce Johnson et al.

Group Art Unit:

Serial No.: 10/691,533

Examiner:

Filed: October 24, 2003

For LABELED LIGANDS FOR LECTIN-LIKE
OXIDIZED LOW-DENSITY LIPOPROTEIN
RECEPTOR (LOX-1)

INFORMATION DISCLOSURE STATEMENT

- ☒ 1 **Pursuant to 37CFR 1.97(b)**
[within 3 months of national, non-CPA filing or prior to 1st Office Action] *no charge*
- ☐ 2 **Certification Pursuant to 37 CFR 1.97(c)(1)**
[before Final Office Action, Allowance, or other action closing prosecution] *no charge*
- ☐ 3 **Fee Payment Pursuant to 37 CFR 1.97(c)(2)**
[before Final Office Action, Allowance, or other action closing prosecution] *\$180.00*
- ☐ 4 **Certification & Fee Payment Pursuant to 37 CFR 1.97(d)**
[On or before issue fee payment] *\$180.00*

ATTN: BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The following are submitted in the above application in compliance with 37 CFR 1.97 and 37 CFR 1.98:

- ☒ 5 A list of documents on form PTO-1449 or Substitute together with copies of each identified document and a translation thereof or a concise explanation of each non-English language document or a Search Report from an International Searching Authority for a patent application filed via the Patent Cooperation Treaty or document(s) cited in the application or the priority application.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Date of Deposit_____
Type or Print Name_____
Signature

This paper is submitted in accordance with:

- ☒ 6 37 CFR 1.97(b): [within 3 months of national, non-CPA filing or prior to 1st Office Action]
- ☐ 7 37 CFR 1.97(c): [before Final Office Action, Allowance, or other action closing prosecution, whichever is earlier]; and
- ☐ 8 The required Certification made in item 11 below; or
- ☐ 9 The \$180.00 fee specified in 37 CFR 1.17(p) for submission of this Information Disclosure Statement is authorized in item 15 below.
- ☐ 10 37 CFR 1.97(d): [on or before issue fee payment]; and
- a) The required Certification is stated in item 11 below; and
- b) The \$180.00 fee specified in 37 CFR 1.17(p) for submission of this Information Disclosure Statement is authorized in item 14 below.
- ☒ 11 Certification
- ☐ 12 Each item of information contained in this Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of this Statement; or
- ☒ 13 No item contained in this Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing this document after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR 1.56(c) more than three (3) months prior to the filing date of this Statement.
- ☒ 14 Payment of all applicable fees:
- ☒ 15 Please charge all applicable fees associated with the submittal of this Information Disclosure Statement to Deposit Account No. 07-0868

An original and two (2) copies of this document are enclosed.

January 30, 2004
Date

General Electric Company
CRD Patent Docket Rm 4A59
P.O. Box 8, Bldg. K-1
Schenectady, New York 12301
Customer Number: 006147

Respectfully submitted,

Toan P. Vo

Attorney - Toan P. Vo
Registration No. 43,225
Phone: (518) 387-6648
or (518) 387-7122


Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/691,533
				Filing Date	October 24, 2003
				First Named Inventor	Bruce Johnson et al.
				Group Art Unit	unknown
				Examiner Name	unknown
Sheet	1	of	3	Attorney Docket Number	GE Ref.: 130633

U.S. PATENT DOCUMENTS						
Examiner Initials ⁵	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
		4,752,141		Sun et al.	June 21, 1988	
		4,986,671		Sun et al.	January 22, 1991	
		5,217,456		Narciso, Jr.	June 8, 1993	
		5,275,494		Baker et al.	January 4, 1994	
		5,962,260		Sawamura et al.	Oct. 5, 1999	
		6,197,937		Sawamura et al.	March 6, 2001	
		2002/0006379		Hansen et al.	January 17, 2002	

FOREIGN PATENT DOCUMENTS							
Examiner Initials ⁵	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ² (if known)			
		WO	2002/06771				
		WO	0164862		Kamada Masafumi et al.	2001-09-07	
		EP	1 046 652		Japan Tobacco Inc	2000-10-25	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ⁵	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Wexler et al., Circulation 1996, 94, pp. 1175-1192	
		Brundage et al. In: Fuster V. (Ed.), Syndromes of Atherosclerosis: correlations of clinical imaging and pathology, Armonk, NY: Futura Publishing Company, Inc., 1996, 417-427	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → [+]


PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/691,533
		Filing Date	October 24, 2003
		First Named Inventor	Bruce Johnson et al.
		Group Art Unit	unknown
		Examiner Name	unknown
		Attorney Docket Number	GE Ref.: 130633
2	of	3	



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Orford et al., AM. J. Cardiol, 2000, 86 (suppl.), pp. 6H-11H	
		Fuster et al. N. Engl. J. Med 1992, 326, pp. 242-250	
		Vallabhajosula, S. and Fuster, V., J. Nucl. Med. 1997, 38, pp. 1788-1796	
		Marmion M. and Deutsch, E., J. Nucl. Biol. Med. 1996, 40, pp. 121-131	
		Cerqueira, M.D., Seminars Nucl. Med. 1999, 29, pp. 339-351	
		Narula, J., J. Nucl. Cardiol. 1999, 6, pp. 81-90	
		Narula, J. Nucl. Med. Commun. 2000, 21, pp. 601-608	
		Meaney et al. J. Magn. Reson. Imaging 1999, 10 pp. 326-338	
		Knopp et al. J. Magn. Reson. Imaging 1999, 10, pp. 314-316	
		Goyen et al. Eur. J. Radio. 2000, 34 pp. 247-256	
		Becker et al. Eur. Radiol, 2000, 10, pp. 629-635	
		Doyle, M. and Pohost, G. In: Fuster, V. (Ed.), Syndromes of Atherosclerosis: correlations of clinical imaging and pathology, Armonk, NY: Futura Publishing Company, Inc. 1996, pp 313-332	
		Grist, T. and Turski, P.A. In: Fuster, V. (Ed.), Syndromes of Atherosclerosis: correlations of clinical imaging and pathology, Armonk, NY: Futura Publishing Company, Inc. 1996, pp. 333-362	
		Yuan et al., J. Magn. Reson. Imaging 1994 4, pp. 43-49	
		Toussaint et al. Atheroscler. Thromb. 1995, 15, pp. 1533-1542	
		Toussaint et al., Circulation 1996, 94, pp. 932-938	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → [+]


PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/691,533
				Filing Date	October 24, 2003
				First Named Inventor	Bruce Johnson et al.
				Group Art Unit	unknown
				Examiner Name	unknown
Sheet	3	of	3	Attorney Docket Number	GE Ref.: 130633



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	ER: M. Veitch	E.R. Magn. Reson. Imaging 1996, 14, pp. 137-150	
		Glover, G. D. and Herfkens, R. J. Radiology 1998, 207, pp 289-235	
		Ross, R. Nature 1993, 362, pp. 802-809	
		Steinberg, D. J. Biol. Chem. 1997, 272, pp. 29063-29066	
		Tsimikas, S. Arteriosclerosis, Thrombosis, and Vascular Biology 2000, 20, pp. 689-697	
		Shaish, A. et al., Pathobiology 2001, 69, pp. 225-229	
		Iuliano, L. et al., Atherosclerosis 1996, 126, pp. 131-141	
		Sawamura, T. Nature 1997, 386, pp. 73-77	
		Yoshida, H. et al., Biochem. J. 1998, 334, pp. 9-13	
		Kataoka, H. et al., Circulation 1999, 99, pp. 3110-3117	
		White, S. et al., Hypertension 2001, 37, pp. 449-455	
		Chen, M., et al., J. Biochem., 355, pp. 289-295 (2001)	
		Arterioscler Thromb Vasc Biol. 1998, 18, pp. 1541-1547	
		Delneste, Y., et al., Involvement of LOX-1 in dendritic cell mediated antigen cross presentation, Immunity, 17 (3), pp. 353-362 (2002)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.